


# Cortellis Generic Intelligence

## Find Paragraph IV Patent Challenge Commentaries?


Learn how to find the Paragraph IV Challenge Commentaries in Cortellis Generics Intelligence. The Newport Research Team monitors and collects information on Paragraph IV Patent Challenges and updates the content daily.

Example: Find the US Patent Challenge commentary for rivaroxaban.

1. Use the Quick Search tool to find the rivaroxaban record.



2. In the product record click the US Patent Challenges Tab. The streamlined design allows you to open the table and view data on the Filters, the patents litigated, the approval date and more.




Product Key Insights > US Patent Challenges


**rivaroxaban** Alert

Product Key Insights | API Manufacturers | Regulatory Filings | Approvals | Launches & Pack Prices | Constraint Date Forecast & Exclusivities | Patents & SPCs | **US Patent Challenges** | Deals | Competitive Insights | R&D | Scientific

XARELTO  
NDA- 022406


Dose Form: Tablet | Route: Oral | Strength: 10MG, 15MG, 2.5MG, 20MG View Commentaries

US Patent Challenges 


FILER 	ASSOCIATED COMPANIES	APPLICATION NUMBER	STRENGTH	PATENTS LITIGATED	SUBMISSION/ NOTIFICATION DATE	30 MONTH STAY	LITIGATION STATUS	APPROVAL DATE	LAUNCH DATE	COMMENTARY
Atembic Pharmaceuticals Ltd	No data	210301 (ANDA)	10mg, 15mg, 20mg	US-09539218	No data	No data	Closed	Filed	No data	By letter dated April 21, 2017, Bayer and Janssen received notice of Atembic's ANDA with Paragraph IV certification for a generic...
Aurobindo Pharma Ltd First to File: Assumed	No data	208544 (ANDA)	10mg, 15mg, 20mg	US-07157456 US-07585860 US-07592339 US-09539218	No data	No data	Closed	22-Jun-2018: Tentative	No data	By letter dated September 24, 2015, Bayer and Janssen received notice of Aurobindo's ANDA with Paragraph IV certification for a

Click this icon to open the table.

- Click the View Commentaries button to open a pop up of an exportable PIV Patent Challenge Commentary.




Search within the commentary.

 View Commentaries

Export to PDF

janssen

 Export

### XARELTO NDA 022406

Information about an ANDA with Paragraph IV certification for a generic version of Xarelto (rivaroxaban) tablets, 10mg, 15mg, and 20mg first appeared on the FDA website as of September 8, 2015. The FDA reports a submission date of July 1, 2015, which was the first day an ANDA could have been submitted for a rivaroxaban product. The New Chemical Entity exclusivity for rivaroxaban expired on July 1, 2016. The FDA reports eight ANDAs for generic versions of Xarelto tablets, 10mg, 15mg, and 20mg were filed on the first day possible and may share eligibility for the 180-day generic drug exclusivity.

Information about an ANDA with Paragraph IV certification for a generic version of Xarelto tablets, 2.5mg first appeared on the FDA website as of December 3, 2018. The FDA reports a submission date of November 19, 2018. According to the FDA, four ANDAs for generic versions of Xarelto tablets, 2.5mg were filed on the same day and may share eligibility for the 180-day generic drug exclusivity for that strength.

#### Alembic Pharmaceuticals Ltd: 210301 (ANDA)

By letter dated April 21, 2017, Bayer and **Janssen** received notice of Alembic's ANDA with Paragraph IV certification for a generic version of Xarelto tablets. On June 2, 2017, Bayer and **Janssen** filed a patent infringement suit against Alembic in the U.S. District Court for the District of Delaware in response to Alembic's ANDA. Bayer and **Janssen** alleged infringement of U.S. Patent 9,539,218. <sup>1</sup> On November 13, 2017, the Delaware court consolidated the Alembic, Aurobindo, Breckenridge, InvaGen, Lupin, Micro Labs, Mylan, Sigmapharm, Taro, and Torrent cases concerning U.S. Patent 9,539,218. <sup>2</sup> On June 15, 2018, the Delaware court stayed the case concerning U.S. Patent 9,539,218 with respect to Alembic and the parties agreed to be bound by any final judgment on the merits in the remaining consolidated action. <sup>3</sup> Trial in the consolidated case concerning U.S. Patent 9,539,218 began on April 5, 2019. <sup>4</sup> On March 2, 2020, the parties to the Lupin litigation stipulated to the dismissal of the matter with prejudice. <sup>5</sup> To our knowledge, no patent settlement terms have been disclosed. Alembic holds a DMF for rivaroxaban.

Search terms are highlighted.

1: Bayer Intellectual Property GmbH et al. v. Alembic Pharmaceuticals Limited et al., U.S. District Court, D. Delaware, Case 1:17-cv-00675, 2017-06-02

2: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2017-11-13

3: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2018-06-15

4: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2019-04-05

5: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2020-03-02

For more information contact Customer Service at [LS Product Support](#)